Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The Chronic Hypersensitivity Pneumonitis (HP), is an inflammatory disease who has an
evolution to develop progressive interstitial fibrosis, who cause the death of the patient.
Actually HP has been treated with Prednisone and occasionally with Azathioprine, but
unfortunately the treatment with these drugs have not an effective result to treat the
interstitial fibrosis.
Pirfenidone has been studied over the world for the treatment of Fibrotic diseases, with
positive results, and due to the Pirfenidone mechanism of action has anti-inflammatory and
anti-fibrotic properties, the investigators propose to evaluate the addition of Pirfenidone
to the actual treatment with Prednisone and Azathioprine in the treatment of patients with
Pulmonary Fibrosis secondary to a Chronic Hypersensitivity Pneumonitis.